ESMO 2018 Congress | OncologyPRO

Abstract 4300

Background

Cabazitaxel is approved for patients with mCRPC, post docetaxel. The CUP (CABAZ_C_05005) and EAP (NCT01254279) provided access to cabazitaxel before commercial availability and assessed real-world safety. CAPRISTANA (CABAZC 06092), a prospective, observational study, evaluated the routine clinical use of cabazitaxel. In this analysis we examined factors associated with cabazitaxel treatment duration in a real-life setting.

Methods

Patients ≥18 years of age with mCRPC previously treated with docetaxel, received cabazitaxel 25 mg/m² intravenously every 3 weeks until disease progression, death, unacceptable toxicity or physician/patient decision. Of note, treatment was capped at 10 cycles in some countries.

Results

The CUP/EAP/CAPRISTANA studies combined included 1,621 patients (CUP/EAP, N = 1,432; CAPRISTANA, N = 189). The median number of cabazitaxel cycles received was 6. Overall, 708 patients (43.7%) received >6 cycles (Table); 211 (13.0%) received >10 cycles. For patients receiving >10 cycles, the median number of cabazitaxel cycles received was 14. Patients receiving more cabazitaxel cycles tended to have better ECOG performance status of 0–1 (Table; P = 0.0017 for ≤6 vs > 6 cycles). In total, 348 patients (21.5%) were ≥75 years of age, of which 40% (n = 139) received >6 cabazitaxel cycles. Further analysis into the patient subgroups and reasons for treatment discontinuation are ongoing.Table: 818P

	CUP/EAP/CAPRISTANA N = 1,621
Cabazitaxel cycles received
≤6 N = 913	>6 N = 708
Median age, years (range)	68.0 (42–89)	68.0 (43–89)
Age, n (%) <65 years 65–75 years ≥75 years	271 (29.7) 433 (47.4) 209 (22.9)	230 (32.5) 339 (47.9) 139 (19.6)
ECOG PS, n (%) 0–1 2*	N = 912 816 (89.5) 96 (10.5)	N = 708 665 (93.9) 43 (6.1)
Median cabazitaxel cycles, n (range)	4 (1–6)	10 (7–49)
Median duration of cabazitaxel exposure, months (range)	2.8 (1–6)	6.9 (5–35)
Median time from prostate cancer diagnosis, years (range)	4.5 (0–22)	4.7 (0–20)
Median time from mCRPC diagnosis, years (range)	1.7 (0–14)	1.8 (0–12)
Median docetaxel cycles at last administration, n (range)	7 (1–69)	8 (1–58)
Metastatic sites, n (%) Bone Visceral Regional lymph nodes	N = 912 829 (90.8) 47 (5.1) 282 (30.9)	N = 707 630 (89.0) 23 (3.2) 214 (30.2)
G-CSF during Cycle 1, n (%) Prophylactic Therapeutic Both	N = 499 385 (42.2) 69 (7.6) 45 (4.9)	N = 380 314 (44.4) 33 (4.7) 33 (4.7)
Pain at baseline (CAPRISTANA study only), n (%) None Moderate Severe	N = 86 15 (17.4) 63 (73.3) 8 (9.3)	N = 68 18 (26.5) 47 (69.1) 3 (4.4)

Includes one patient with ECOG PS 3 receiving ≤6 cabazitaxel cycles.

Conclusions

Cabazitaxel was well tolerated by patients across these global studies, including elderly patients. Many patients derived benefit from cabazitaxel and went on to receive a greater number of cycles. Further analyses may identify prognostic factors that could indicate which patients are likely to receive >6 cabazitaxel cycles and derive greater benefit. Funding: Sanofi.

Clinical trial identification

Compassionate Use Program (CUP): CABAZ_C_05005. Expanded Access Program (EAP): NCT01254279. CAPRISTANA Registry Study: CABAZC 06092.

Legal entity responsible for the study

Sanofi.

Funding

Sanofi.

Editorial Acknowledgement

Editorial assistance was provided by Danielle Lindley of Meditech Media Ltd, funded by Sanofi.

Disclosure

Z. Malik: Advisory boards, speaker meetings: Sanofi. U. De Giorgi: Consultancy fees: Sanofi, Astellas, Janssen, Bristol-Myers Squibb, Ipsen, Novartis, Pfizer. S. Hitier, E. Ecstein-Fraisse, A. Ozatilgan: Employee: Sanofi. J. Carles: Consultancy, advisory role: Johnson & Johnson, Astellas Pharma, Bayer, Amgen, Pfizer, Bristol-Myers Squibb, Sanofi; Speakers' bureau: Bayer, Johnson & Johnson. All other authors have declared no conflicts of interest.

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4300 - Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry

Date

Session

Topics

Tumour Site

Presenters

Citation

Authors

Author affiliations

Resources

Abstract 4300

Background

Methods

Results

Conclusions

Clinical trial identification

Legal entity responsible for the study

Funding

Editorial Acknowledgement

Disclosure

Abstract 4300

Background

Methods

Results

Conclusions

Clinical trial identification

Legal entity responsible for the study

Funding

Editorial Acknowledgement

Disclosure

Resources from the same session